Post-HSCT Viral Management: Strategies Beyond the Guidelines (ICBMT 2025) - Sep 3, 2025 - Abstract #SS09-3; Pres time: Sep 13, 2025; 09:00 AM - 10:30 AM; "Despite the integration of Letermovir into standard prophylaxis regimens, breakthrough infections persist, especially beyond D+100, with Korean real-world data showing clinically significant CMV infection (csCMVi) rates rising from 9.5% at 14 weeks to 29.4% by 24 weeks...We present a real-world case of ganciclovir-resistant CMV harbouring the UL97 H520Q mutation, which necessitated sequential therapy with foscarnet and later maribavir...Prophylaxis with oral acyclovir for up to one year reduces early incidence but carries rebound risks and is limited by long-term toxicity and antiviral resistance. The advent of the recombinant zoster vaccine (RZV; Shingrix) offers a promising preventive strategy, particularly in the 6–24 month window post-transplant...Optimal outcomes require a personalised, adaptive strategy that incorporates novel therapeutics, surveillance tools, and host factors. Through real-world evidence and clinical insight, this lecture aims to equip..."
Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Herpes Zoster • Immunology • Infectious Disease • Varicella Zoster
|